Diagnosis of invasive aspergillosis: Recent developments and ongoing challenges

European Journal of Clinical Investigation

Volumn 45, Issue 6, 2015, Pages 646-652

  Arvanitis, Marios ^a,b,c   Mylonakis, Eleftherios ^a,b  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c BOSTON MEDICAL CENTER   (United States)

Author keywords

Aspergillus; PCR; Aspergillosis; Galactomannan; Lateral flow device; Volatile compounds

Indexed keywords

BETA GLUCAN; GALACTOMANNAN; VOLATILE ORGANIC COMPOUND; MANNAN;

ASPERGILLUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC VALUE; FUNGAL DETECTION; FUNGUS CULTURE; HISTOPATHOLOGY; HUMAN; INVASIVE ASPERGILLOSIS; LATERAL FLOW DEVICE; MOLECULAR DIAGNOSIS; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCREENING; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; STANDARDIZATION; SYSTEMATIC REVIEW; ASPERGILLOSIS; EARLY DIAGNOSIS; METABOLISM; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION;

ASPERGILLOSIS; BETA-GLUCANS; EARLY DIAGNOSIS; HUMANS; MANNANS; REAL-TIME POLYMERASE CHAIN REACTION; VOLATILE ORGANIC COMPOUNDS;

EID: 84929504197     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12448     Document Type: Review

References (49)

1. Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002;20:1898-906.
2. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996;100:171-8.
3. Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L, Chapman SW et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001;33:1824-33.
4. Zmeili OS, Soubani AO. Pulmonary aspergillosis: a clinical update. QJM 2007;100:317-34.
5. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60.
6. Hot A, Maunoury C, Poiree S, Lanternier F, Viard JP, Loulergue P et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect 2011;17:409-17.
7. Kim JY, Yoo JW, Oh M, Park SH, Shim TS, Choi YY et al. (18)F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography findings are different between invasive and noninvasive pulmonary aspergillosis. J Comput Assist Tomogr 2013;37:596-601.
8. Sharma P, Mukherjee A, Karunanithi S, Bal C, Kumar R. Potential role of 18F-FDG PET/CT in patients with fungal infections. AJR Am J Roentgenol 2014;203:180-9.
9. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21.
10. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
11. Borlenghi E, Cattaneo C, Capucci MA, Pan A, Quaresmini G, Franco F et al. Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates. Ann Hematol 2007;86:205-10.
12. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, Scholten RJ, Hooft L, Bijlmer HA et al. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev 2008;(4):CD007394.
13. Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev 2014;27:490-526.
14. Viscoli C, Machetti M, Cappellano P, Bucci B, Bruzzi P, Van Lint MT et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004;38:913-6.
15. Mikulska M, Furfaro E, Del Bono V, Raiola AM, Ratto S, Bacigalupo A et al. Piperacillin/tazobactam (Tazocin) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother 2012;67:1746-8.
16. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006;42:1417-27.
17. Guo YL, Chen YQ, Wang K, Qin SM, Wu C, Kong JL. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest 2010;138:817-24.
18. Heng SC, Morrissey O, Chen SC, Thursky K, Manser RL, Nation RL et al. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis. Crit Rev Microbiol 2015;41:124-34.
19. Affolter K, Tamm M, Jahn K, Halter J, Passweg J, Hirsch HH et al. Galactomannan in bronchoalveolar lavage for diagnosing invasive fungal disease. Am J Respir Crit Care Med 2014;190:309-17.
20. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005;40:1762-9.
21. Peikert T, Rana S, Edell ES. Safety, diagnostic yield, and therapeutic implications of flexible bronchoscopy in patients with febrile neutropenia and pulmonary infiltrates. Mayo Clin Proc 2005;80:1414-20.
22. Sampsonas F, Kontoyiannis DP, Dickey BF, Evans SE. Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study. Cancer 2011;117:3424-33.
23. Marty FM, Koo S. Role of (1->3)-beta-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol 2009;47(Suppl 1):S233-40.
24. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005;5:609-22.
25. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011;52:750-70.
26. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1, 3-beta-D-glucan assay reactivity. Clin Infect Dis 2008;46:1930-1.
27. Thornton CR. Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol 2008;15:1095-105.
28. White PL, Parr C, Thornton C, Barnes RA. Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay (ELISA), and a novel lateral-flow device for diagnosis of invasive aspergillosis. J Clin Microbiol 2013;51:1510-6.
29. Hoenigl M, Koidl C, Duettmann W, Seeber K, Wagner J, Buzina W et al. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. J Infect 2012;65:588-91.
30. Prattes J, Flick H, Pruller F, Koidl C, Raggam RB, Palfner M et al. Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases. Am J Respir Crit Care Med 2014;190:922-9.
31. Syhre M, Scotter JM, Chambers ST. Investigation into the production of 2-Pentylfuran by Aspergillus fumigatus and other respiratory pathogens in vitro and human breath samples. Med Mycol 2008;46:209-15.
32. Chambers ST, Syhre M, Murdoch DR, McCartin F, Epton MJ. Detection of 2-pentylfuran in the breath of patients with Aspergillus fumigatus. Med Mycol 2009;47:468-76.
33. de Heer K, van der Schee MP, Zwinderman K, van den Berk IA, Visser CE, van Oers R et al. Electronic nose technology for detection of invasive pulmonary aspergillosis in prolonged chemotherapy-induced neutropenia: a proof-of-principle study. J Clin Microbiol 2013;51:1490-5.
34. Koo S, Thomas HR, Daniels SD, Lynch RC, Fortier SM, Shea MM et al. A breath fungal secondary metabolite signature to diagnose invasive aspergillosis. Clin Infect Dis 2014;59:1733-40.
35. Kontoyiannis DP, Patterson TF. Diagnosis and treatment of invasive fungal infections in the cancer patient: recent progress and ongoing questions. Clin Infect Dis 2014;59(Suppl 5):S356-9.
36. Heddergott C, Calvo AM, Latge JP. The volatome of Aspergillus fumigatus. Eukaryot Cell 2014;13:1014-25.
37. Yamakami Y, Hashimoto A, Tokimatsu I, Nasu M. PCR detection of DNA specific for Aspergillus species in serum of patients with invasive aspergillosis. J Clin Microbiol 1996;34:2464-8.
38. Arvanitis M, Ziakas PD, Zacharioudakis IM, Zervou FN, Caliendo AM, Mylo nakis E. PCR in diagnosis of invasive aspergillosis: a meta-analysis of diagnostic performance. J Clin Microbiol 2014;52:3731-42.
39. Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9:89-96.
40. White PL, Bretagne S, Klingspor L, Melchers WJ, McCulloch E, Schulz B et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010;48:1231-40.
41. White PL, Mengoli C, Bretagne S, Cuenca-Estrella M, Finnstrom N, Klingspor L et al. Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol 2011;49:3842-8.
42. Springer J, Morton CO, Perry M, Heinz WJ, Paholcsek M, Alzheimer M et al. Multicenter comparison of serum and whole-blood specimens for detection of Aspergillus DNA in high-risk hematological patients. J Clin Microbiol 2013;51:1445-50.
43. Bernal-Martinez L, Gago S, Buitrago MJ, Gomez-Lopez A, Rodriguez-Tudela JL, Cuenca-Estrella M. Analysis of performance of a PCR-based assay to detect DNA of Aspergillus fumigatus in whole blood and serum: a comparative study with clinical samples. J Clin Microbiol 2011;49:3596-9.
44. Sun W, Wang K, Gao W, Su X, Qian Q, Lu X et al. Evaluation of PCR on bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis: a bivariate metaanalysis and systematic review. PLoS ONE 2011;6:e28467.
45. Avni T, Levy I, Sprecher H, Yahav D, Leibovici L, Paul M. Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review. J Clin Microbiol 2012;50:3652-8.
46. Pham CD, Reiss E, Hagen F, Meis JF, Lockhart SR. Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011-2013. Emerg Infect Dis 2014;20:1498-503.
47. Powers JH. Issues in clinical trials of prophylaxis of fungal infections. Clin Infect Dis 2004;39(Suppl 4):S211-7.
48. Morrissey CO, Chen SC, Sorrell TC, Milliken S, Bardy PG, Bradstock KF et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis 2013;13:519-28.
49. Aguado JM, Vazquez L, Fernandez-Ruiz M, Villaescusa T, Ruiz-Camps I, Barba P et al. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. Clin Infect Dis 2015;60:405-14.